πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 837 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12070506

Steroids and antibody-conjugates thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12066246

Target residual moisture content for lyophilized drug product

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12068729

Anti-factor XII/XIIa antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12065506

Anti-TMPRSS2 antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12060419

CD79A chimeric antigen receptors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12060428

Anti-IL36R antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054532

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12053534

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054533

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12054557

Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049670

Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049489

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042538

Methods of reducing particle formation and compositions formed thereby

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037388

Anti-IL-33 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037411

Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugat

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036288

Methods of using humanized FCΞ³R mice to assay Fc regions

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12037401

Anti-TrkB monoclonal antibodies and methods of use

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036280

High concentration protein formulation

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036256

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12030935

Anti-PDGF-B antibodies and pharmaceutical composition thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12029788

Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that i

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12024570

Anti-CTLA-4 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12024556

Anti-Staphylococcus antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018259

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibito

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted